Novogen (KZIA) Competitors

Vor Biopharma (NYSE:VOR) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Is VOR or KZIA more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Novogen	N/A	N/A	N/A

Do insiders and institutionals hold more shares of VOR or KZIA?

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 2.9% of Vor Biopharma shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has higher valuation and earnings, VOR or KZIA?

Vor Biopharma has higher earnings, but lower revenue than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$1.51	-1.25
Novogen	$1.51M	4.56	-$17.56M	N/A	N/A

Which has more volatility and risk, VOR or KZIA?

Vor Biopharma has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Novogen has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500.

Do analysts recommend VOR or KZIA?

Vor Biopharma presently has a consensus price target of $5.63, suggesting a potential upside of 198.60%. Novogen has a consensus price target of $57.50, suggesting a potential upside of 742.98%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Novogen	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer VOR or KZIA?

In the previous week, Vor Biopharma had 13 more articles in the media than Novogen. MarketBeat recorded 13 mentions for Vor Biopharma and 0 mentions for Novogen. Vor Biopharma's average media sentiment score of 0.42 beat Novogen's score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Vor Biopharma	Neutral
Novogen	Neutral

Summary

Vor Biopharma beats Novogen on 5 of the 9 factors compared between the two stocks.